- Home
- ABUS vs CDNA Comparison
ABUS vs CDNA Comparison
Compare ABUS & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- CDNA
- Stock Information
- Founded
- ABUS 2005
- CDNA 1998
- Country
- ABUS United States
- CDNA United States
- Employees
- ABUS N/A
- CDNA N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- CDNA Medical Specialities
- Sector
- ABUS Health Care
- CDNA Health Care
- Exchange
- ABUS Nasdaq
- CDNA Nasdaq
- Market Cap
- ABUS 611.0M
- CDNA 712.2M
- IPO Year
- ABUS N/A
- CDNA 2014
- Fundamental
- Price
- ABUS $3.37
- CDNA $11.84
- Analyst Decision
- ABUS Strong Buy
- CDNA Buy
- Analyst Count
- ABUS 3
- CDNA 6
- Target Price
- ABUS $5.67
- CDNA $27.67
- AVG Volume (30 Days)
- ABUS 636.5K
- CDNA 1.5M
- Earning Date
- ABUS 08-06-2025
- CDNA 08-06-2025
- Dividend Yield
- ABUS N/A
- CDNA N/A
- EPS Growth
- ABUS N/A
- CDNA N/A
- EPS
- ABUS N/A
- CDNA 1.00
- Revenue
- ABUS $15,416,000.00
- CDNA $340,826,000.00
- Revenue This Year
- ABUS $3.35
- CDNA $12.81
- Revenue Next Year
- ABUS N/A
- CDNA $13.36
- P/E Ratio
- ABUS N/A
- CDNA $11.85
- Revenue Growth
- ABUS 53.23
- CDNA 14.72
- 52 Week Low
- ABUS $2.71
- CDNA $10.96
- 52 Week High
- ABUS $4.73
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- ABUS 54.05
- CDNA 33.98
- Support Level
- ABUS $3.33
- CDNA $11.73
- Resistance Level
- ABUS $3.45
- CDNA $12.76
- Average True Range (ATR)
- ABUS 0.12
- CDNA 0.64
- MACD
- ABUS 0.01
- CDNA 0.13
- Stochastic Oscillator
- ABUS 36.21
- CDNA 28.61
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.